Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe.
A case is presented of a patient who developed acute hepatitis during cholesterol-lowering treatment with atorvastatin and ezetimibe. Further investigations reveal a probable drug-induced autoimmune hepatitis, and ezetimibe is considered to be the most likely causal agent. This case is the first report of an autoimmune hepatitis associated with ezetimibe therapy.
van Heyningen
Charles
C
Clinical Laboratories, University Hospital Aintree, Lower Lane, Liverpool L9 7AL, UK. charles.vanheyningen@aht.nwest.nhs.uk
D000924:Anticholesteremic Agents / Q000009:adverse effects*; D000069059:Atorvastatin; D001384:Azetidines / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D000069438:Ezetimibe; D005260:Female; D019693:Hepatitis, Autoimmune / Q000209:etiology* / Q000503:physiopathology; D006538:Heptanoic Acids / Q000009:adverse effects*; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000503:physiopathology; D008111:Liver Function Tests; D008875:Middle Aged; D011758:Pyrroles / Q000009:adverse effects*
D000924:Anticholesteremic Agents; D001384:Azetidines; D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin; D000069438:Ezetimibe